Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-05-15
2007-05-15
Huff, Sheela (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S350000, C530S380000, C530S385000, C530S387100, C530S387700, C530S388100, C530S388150, C530S388240, C424S134100, C424S135100, C424S141100, C424S142100, C424S155100, C424S174100, C435S007900, C435S188000, C435S320100
Reexamination Certificate
active
10443466
ABSTRACT:
The present invention includes fully human, neutralizing, monoclonal antibodies against human Insulin-like Growth Factor Receptor-I (IGFR1). The antibodies are useful for treating or preventing cancer in a subject. Also included are methods of using and producing the antibodies of the invention.
REFERENCES:
patent: 4543439 (1985-09-01), Frackelton, Jr. et al.
patent: 5198340 (1993-03-01), Mukku
patent: 5262308 (1993-11-01), Baserga
patent: 5942412 (1999-08-01), Prager et al.
patent: 5958872 (1999-09-01), O'Connor et al.
patent: 5977307 (1999-11-01), Friden et al.
patent: 6022711 (2000-02-01), Cunningham et al.
patent: 6084085 (2000-07-01), Baserga et al.
patent: 6294330 (2001-09-01), Michnick et al.
patent: 6300129 (2001-10-01), Lonberg et al.
patent: 6316462 (2001-11-01), Bishop et al.
patent: 6333031 (2001-12-01), Olsson et al.
patent: 6346390 (2002-02-01), Olsson et al.
patent: 6372250 (2002-04-01), Pardridge
patent: 6537988 (2003-03-01), Lee
patent: 6645775 (2003-11-01), Clark et al.
patent: 2002/0022023 (2002-02-01), Ullrich et al.
patent: 2002/0025313 (2002-02-01), Micklus et al.
patent: 2002/0107187 (2002-08-01), Kingston et al.
patent: 2002/0132275 (2002-09-01), Fidler et al.
patent: 2002/0164333 (2002-11-01), Nemerow et al.
patent: 2002/0169116 (2002-11-01), Kingston et al.
patent: 2002/0187925 (2002-12-01), Kingston et al.
patent: 2002/0197262 (2002-12-01), Hasan et al.
patent: 2003/0021780 (2003-01-01), Smith et al.
patent: 2003/0031658 (2003-02-01), Brodt et al.
patent: 2003/0045676 (2003-03-01), Kingston et al.
patent: 2003/0088061 (2003-05-01), Staunton
patent: 2003/0092631 (2003-05-01), Deshayes et al.
patent: 2003/0138430 (2003-07-01), Stimmel et al.
patent: 2003/0165502 (2003-09-01), Fujita-Yamaguchi
patent: 2003/0195147 (2003-10-01), Pillutla et al.
patent: 2003/0235582 (2003-12-01), Singh et al.
patent: 2003/0236190 (2003-12-01), Pillutla et al.
patent: 2004/0009154 (2004-01-01), Khan et al.
patent: 2004/0009906 (2004-01-01), Kakkis et al.
patent: 2004/0023887 (2004-02-01), Pillutla et al.
patent: 2004/0047835 (2004-03-01), Bianco
patent: 2004/0057950 (2004-03-01), Waksal et al.
patent: 2004/0086511 (2004-05-01), Zack et al.
patent: 2004/0102360 (2004-05-01), Barnett et al.
patent: 2004/0116330 (2004-06-01), Naito et al.
patent: 2004/0142381 (2004-07-01), Hubbard et al.
patent: 2004/0228859 (2004-11-01), Graus et al.
patent: 2004/0265307 (2004-12-01), Singh et al.
patent: 2005/0008642 (2005-01-01), Graus et al.
patent: 2005/0048050 (2005-03-01), Fujita-Yamaguchi
patent: 2005/0069539 (2005-03-01), Cohen et al.
patent: 2005/0084906 (2005-04-01), Goetsch et al.
patent: 2005/0186203 (2005-08-01), Singh et al.
patent: 2005/0244408 (2005-11-01), Cohen et al.
patent: 2005/0249728 (2005-11-01), Singh et al.
patent: 2005/0249730 (2005-11-01), Goetsch et al.
patent: 2005/0272755 (2005-12-01), Denis et al.
patent: 197 19 001 C 2 (2001-05-01), None
patent: 2 834 900 (2003-07-01), None
patent: 2 834 990 (2003-07-01), None
patent: 2 834 991 (2003-07-01), None
patent: WO 91/04014 (1991-04-01), None
patent: WO 91/14438 (1991-10-01), None
patent: WO 97/44352 (1997-11-01), None
patent: WO 98/22092 (1998-05-01), None
patent: WO 98/45427 (1998-10-01), None
patent: WO 99/25378 (1999-05-01), None
patent: WO 99/28347 (1999-06-01), None
patent: WO 99/42127 (1999-08-01), None
patent: WO 99/60023 (1999-11-01), None
patent: WO 00/22130 (2000-04-01), None
patent: WO 00/50067 (2000-08-01), None
patent: WO 00/69454 (2000-11-01), None
patent: WO 00/69454 (2000-11-01), None
patent: WO 01/07084 (2001-02-01), None
patent: WO 01/30964 (2001-05-01), None
patent: WO 01/36632 (2001-05-01), None
patent: WO 01/70268 (2001-09-01), None
patent: WO 01/70930 (2001-09-01), None
patent: WO 01/72771 (2001-10-01), None
patent: WO 01/75064 (2001-10-01), None
patent: WO 02/04522 (2002-01-01), None
patent: WO 02/07783 (2002-01-01), None
patent: WO 02/27017 (2002-04-01), None
patent: WO 02/31500 (2002-04-01), None
patent: WO 02/43758 (2002-06-01), None
patent: WO 02/053596 (2002-07-01), None
patent: WO 02/54066 (2002-07-01), None
patent: WO 02/072780 (2002-09-01), None
patent: WO 2004/87756 (2002-10-01), None
patent: WO 02/88752 (2002-11-01), None
patent: WO 02/092599 (2002-11-01), None
patent: WO 02/102854 (2002-12-01), None
patent: WO 02/102972 (2002-12-01), None
patent: WO 02/102973 (2002-12-01), None
patent: WO 03/000928 (2003-01-01), None
patent: WO 03/14696 (2003-02-01), None
patent: WO 03/027246 (2003-04-01), None
patent: WO 03/039538 (2003-05-01), None
patent: WO 03/59951 (2003-07-01), None
patent: WO 03/088910 (2003-10-01), None
patent: WO 03/106621 (2003-12-01), None
patent: WO 2003/106621 (2003-12-01), None
patent: WO 2004/30625 (2004-04-01), None
patent: WO 2004/30627 (2004-04-01), None
patent: WO 2004/56865 (2004-07-01), None
patent: WO 2004/71529 (2004-08-01), None
patent: WO 2004/83248 (2004-09-01), None
patent: WO2004/96224 (2004-11-01), None
patent: WO 2005/05635 (2005-01-01), None
patent: WO 2005/016967 (2005-02-01), None
patent: WO 2005/16970 (2005-02-01), None
patent: WO 2005/016970 (2005-02-01), None
patent: WO 2005/016970 (2005-02-01), None
patent: WO 2005/61541 (2005-07-01), None
patent: WO2005/117980 (2005-12-01), None
Rudikoff et al (Proc Natl Acad USA 1982 vol. 79 p. 1979).
Burgess et al, Journal of Cell Biology vol. 111 Nov. 1990 2129-2138.
Lazar et al Molecular and Cellular Biology Mar. 1988 vol. 8 No. 3 1247-1252.
Schwartz et al, Proc Natl Acad Sci USA vol. 1987 84:6408-6411.
Lin et al Biochemistry USA vol. 14:1559-1563 (1975).
Acland et al., Nature vol. 343:662-665 (1990).
Cordera et al (Biochem Biophys Res Commun. Nov. 15, 1985;132(3):991-1000).
Freund et al (Cancer Research 1994, 54(12):3179-3185).
Sachdev et al (Cancer Research. 2003. 63:627-635).
Cohen et al (Clinical Cancer Research. 2005. 11:2063-2073).
Hailey et al (Molecular Cancer Therapeutics. 2002. 1:1349-1353).
Li et al., “Single-chain antibodies against human insulin-like growth factor 1 receptor: expression, purification, and effect on tumor growth”, Cancer Immunol. Immunother. 49: 243-252 (2000).
Burtrum et al., “A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.” Cancer Res. Dec. 15, 2003;63(24):8912-21.
Business Wire, “Imclone systems incorporated reports advancements in several pipeline programs” (Jul. 14, 2003).
Zhenping Zhu, “Monoclonal Antibodies in Cancer-Fourth International Congress (Part II), Colorado Springs, CO, USA” Investigational Drug Database Meeting Report (Sep. 3-6, 2004).
Laura Williams, “American Association for Cancer Research-94thAnnual Meeting (Part III)- Overnight Report, Washington, D.C., USA” Investigational Drug Database Meeting Report (Jul. 11-14, 2003).
Imclone Systems, Inc. Form 10-K (filed Mar. 15, 2004).
Happerfield, et al., “The localization of insulin-like growth factor receptor 1 (IGFR1) in benign and malignant breast tissue” Journal of Pathology 183:412-417 (1997).
Search Report for International Application No. PCT/US03/16283.
R&D Systems catalogue pages-monoclonal anti-IGF-IR antibody MAB391.
Xiong et al., “Growth-stimulatory monoclonal antibodies against human insulin-like growth factor I receptor” Proc. Nat. Acad. Sci. 89: 5356-5360 (1992).
Li et al., “Two new monoclonal antibodies against the α subunit of the human insulin-like growth factor-I receptor” Biochem. Biophys. Res. Comm. 196(1):92-98 (1993).
Kull et al., “Monoclonal antibodies to receptors for insulin and somatomedin-C” J. Biol. Chem. 258(10):6561-6566 (1983).
Butler et al., “Insulin-like growth factor-I receptor signal transduction: at the interface between physiology and cell biology” Comp. Biochem. Physiol. (B) 121(1):19-26 (1998).
Chan et al., “Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study” Science. 279(5350):563-566 (1998).
Xie et al., “Expression of insulin-like growth factor-1 receptor in synovial sar
Brams Peter
Feingersh Diane
Greenberg Robert
Hailey Judith
Pachter Jonathan A.
Huff Sheela
Schering Corporation
Tungaturthi Parithosh K.
LandOfFree
Neutralizing human anti-IGFR antibody does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neutralizing human anti-IGFR antibody, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neutralizing human anti-IGFR antibody will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3788203